Free Trial
NASDAQ:KZR

Kezar Life Sciences (KZR) Stock Price, News & Analysis

Kezar Life Sciences logo
$4.04 +0.21 (+5.48%)
As of 03:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Kezar Life Sciences Stock (NASDAQ:KZR)

Key Stats

Today's Range
$3.88
$4.08
50-Day Range
$3.83
$6.16
52-Week Range
$3.62
$9.18
Volume
14,796 shs
Average Volume
31,363 shs
Market Capitalization
$29.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.50
Consensus Rating
Hold

Company Overview

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Kezar Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

KZR MarketRank™: 

Kezar Life Sciences scored higher than 82% of companies evaluated by MarketBeat, and ranked 181st out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kezar Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Kezar Life Sciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Kezar Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Kezar Life Sciences are expected to decrease in the coming year, from ($4.39) to ($8.31) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kezar Life Sciences is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kezar Life Sciences is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Kezar Life Sciences has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Kezar Life Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    1.11% of the float of Kezar Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Kezar Life Sciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Kezar Life Sciences has recently increased by 1.32%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Kezar Life Sciences does not currently pay a dividend.

  • Dividend Growth

    Kezar Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.11% of the float of Kezar Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Kezar Life Sciences has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Kezar Life Sciences has recently increased by 1.32%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Kezar Life Sciences has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Kezar Life Sciences this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Kezar Life Sciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.40% of the stock of Kezar Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    67.90% of the stock of Kezar Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Kezar Life Sciences' insider trading history.
Receive KZR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

KZR Stock News Headlines

Q2 EPS Forecast for Kezar Life Sciences Increased by Analyst
Elon’s 2025 Silver Crisis (What It Means for You)
Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.
Kezar Life Sciences price target lowered to $7 from $9 at Wells Fargo
Kezar Life Sciences reports topline results from PORTOLA trial
See More Headlines

KZR Stock Analysis - Frequently Asked Questions

Kezar Life Sciences' stock was trading at $6.72 on January 1st, 2025. Since then, KZR shares have decreased by 40.3% and is now trading at $4.0150.
View the best growth stocks for 2025 here
.

Kezar Life Sciences, Inc. (NASDAQ:KZR) released its quarterly earnings data on Tuesday, May, 13th. The company reported ($2.27) EPS for the quarter, beating the consensus estimate of ($2.56) by $0.29.

Kezar Life Sciences's stock reverse split before market open on Wednesday, October 30th 2024. The 1-10 reverse split was announced on Monday, October 28th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Kezar Life Sciences (KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.

Kezar Life Sciences' top institutional investors include BML Capital Management LLC (5.59%), Acadian Asset Management LLC (1.83%), Stonepine Capital Management LLC (1.37%) and Goldman Sachs Group Inc. (0.39%). Insiders that own company stock include Morningside Venture Investment and Mark C Schiller.
View institutional ownership trends
.

Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kezar Life Sciences investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Bank of America (BAC), Abbott Laboratories (ABT) and Zomedica (ZOM).

Company Calendar

Last Earnings
5/13/2025
Today
5/28/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KZR
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.50
High Stock Price Target
$70.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+883.8%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$101.87 million
Pretax Margin
-1,408.11%

Debt

Sales & Book Value

Annual Sales
$7 million
Price / Cash Flow
N/A
Book Value
$25.80 per share
Price / Book
0.16

Miscellaneous

Free Float
6,617,000
Market Cap
$29.33 million
Optionable
Not Optionable
Beta
0.61
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:KZR) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners